5588 related articles for article (PubMed ID: 3978657)
1. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
2. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma.
Murphy KT; Wardak A; Beckett MA; Lopez CA; Mehta N; Kimchi E; Salloum RM; Jaskowiak NT; Posner MC; Ohno T; Kufe DW; Weichselbaum RR; Mauceri HJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):317-21. PubMed ID: 15887016
[TBL] [Abstract][Full Text] [Related]
3. [Enhancement of immune response by an antitumor agent, cyclophosphamide].
Nitta K; Tanaka T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):706-13. PubMed ID: 2938546
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
5. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antitumor effect of cyclophosphamide by thaliblastine in Lewis lung carcinoma and L1210 leukemia in mice.
Stoychkov JN; Miloushev AS
Biomedicine; 1980 Apr; 33(2):42-4. PubMed ID: 6447522
[TBL] [Abstract][Full Text] [Related]
7. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW; Biro TG
Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic cell therapy for a murine mammary carcinoma.
Morecki S; Yacovlev E; Diab A; Slavin S
Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of forphenicinol, a low molecular weight immunomodifier, on murine transplantable tumors and microbial infections.
Ishizuka M; Masuda T; Kanbayashi N; Watanabe Y; Matsuzaki M; Sawazaki Y; Ohkura A; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1982 Aug; 35(8):1049-54. PubMed ID: 7142006
[TBL] [Abstract][Full Text] [Related]
12. Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4.
Okura A; Naito K; Iizuka H; Ishizuka M; Takeuchi T; Umezawa H
J Biol Response Mod; 1987 Feb; 6(1):35-43. PubMed ID: 3559627
[TBL] [Abstract][Full Text] [Related]
13. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors.
Wietrzyk J; Opolski A; Madej J; Radzikowski C
Acta Pol Pharm; 2000 Nov; 57 Suppl():5-8. PubMed ID: 11293263
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
Ujiie T
Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid.
Youn JK; Lacour F; Hue G
Cancer Res; 1982 Nov; 42(11):4706-11. PubMed ID: 7127305
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
Kedar E; Chriqui-Zeira E; Kyriazis AP
J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
[TBL] [Abstract][Full Text] [Related]
18. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
Fisher B; Gebhardt M
Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]